全文获取类型
| 收费全文 | 142699篇 |
| 免费 | 8224篇 |
| 国内免费 | 539篇 |
专业分类
| 耳鼻咽喉 | 1620篇 |
| 儿科学 | 3540篇 |
| 妇产科学 | 2326篇 |
| 基础医学 | 18554篇 |
| 口腔科学 | 2898篇 |
| 临床医学 | 13967篇 |
| 内科学 | 30420篇 |
| 皮肤病学 | 2782篇 |
| 神经病学 | 12797篇 |
| 特种医学 | 6093篇 |
| 外国民族医学 | 11篇 |
| 外科学 | 22230篇 |
| 综合类 | 1755篇 |
| 一般理论 | 94篇 |
| 预防医学 | 10508篇 |
| 眼科学 | 3121篇 |
| 药学 | 8978篇 |
| 9篇 | |
| 中国医学 | 230篇 |
| 肿瘤学 | 9529篇 |
出版年
| 2023年 | 841篇 |
| 2022年 | 1313篇 |
| 2021年 | 3019篇 |
| 2020年 | 1939篇 |
| 2019年 | 2870篇 |
| 2018年 | 3163篇 |
| 2017年 | 2491篇 |
| 2016年 | 2735篇 |
| 2015年 | 3100篇 |
| 2014年 | 4429篇 |
| 2013年 | 6009篇 |
| 2012年 | 8987篇 |
| 2011年 | 9560篇 |
| 2010年 | 5447篇 |
| 2009年 | 5245篇 |
| 2008年 | 8604篇 |
| 2007年 | 8945篇 |
| 2006年 | 8904篇 |
| 2005年 | 8987篇 |
| 2004年 | 8254篇 |
| 2003年 | 7667篇 |
| 2002年 | 7320篇 |
| 2001年 | 1958篇 |
| 2000年 | 1676篇 |
| 1999年 | 1873篇 |
| 1998年 | 1698篇 |
| 1997年 | 1368篇 |
| 1996年 | 1191篇 |
| 1995年 | 1159篇 |
| 1994年 | 1028篇 |
| 1993年 | 921篇 |
| 1992年 | 1195篇 |
| 1991年 | 1106篇 |
| 1990年 | 957篇 |
| 1989年 | 933篇 |
| 1988年 | 849篇 |
| 1987年 | 834篇 |
| 1986年 | 825篇 |
| 1985年 | 751篇 |
| 1984年 | 820篇 |
| 1983年 | 736篇 |
| 1982年 | 884篇 |
| 1981年 | 790篇 |
| 1980年 | 678篇 |
| 1979年 | 606篇 |
| 1978年 | 585篇 |
| 1977年 | 515篇 |
| 1976年 | 477篇 |
| 1974年 | 456篇 |
| 1973年 | 401篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
1.
Michelle Lerman Julia A. Gaebler Sunday Hoy Jessica Izhakoff Laura Gullett Timothy Niecko Pinar Karaca-Mandic Thomas O&#x;Donnell Stanley G. Rockson 《Journal of vascular surgery》2019,69(2):571-580
Objective
Phlebolymphedema (chronic venous insufficiency-related lymphedema) is a common and costly condition. Nevertheless, there is a dearth of evidence comparing phlebolymphedema therapeutic interventions. This study sought to examine the medical resource utilization and phlebolymphedema-related cost associated with Flexitouch (FLX; Tactile Medical, Minneapolis, Minn) advanced pneumatic compression devices (APCDs) relative to conservative therapy (CONS) alone, simple pneumatic compression devices (SPCDs), and other APCDs in a representative U.S. population of phlebolymphedema patients.Methods
This was a longitudinal matched case-control analysis of deidentified private insurance claims. The study used administrative claims data from Blue Health Intelligence for the complete years 2012 through 2016. Patients were continuously enrolled for at least 18 months, diagnosed with phlebolymphedema, and received at least one claim for CONS either alone or in addition to pneumatic compression (SPCDs or APCDs). The main outcomes included direct phlebolymphedema- and sequelae-related medical resource utilization and costs.Results
After case matching, the study included 86 patients on CONS (87 on FLX), 34 on SPCDs (23 on FLX), and 69 on other APCDs (67 on FLX). Compared with CONS, FLX was associated with 69% lower per patient per year total phlebolymphedema- and sequelae-related costs net of any pneumatic compression device-related costs ($3839 vs $12,253; P = .001). This was driven by 59% fewer mean annual hospitalizations (0.13 vs 0.32; P < .001) corresponding to 82% lower inpatient costs and 55% lower outpatient hospital costs. FLX was also associated with 52% lower outpatient physical therapy and occupational therapy costs and 56% lower other outpatient-related costs. Compared with SPCDs, FLX was associated with 85% lower total costs ($1153 vs $7449; P = .008) driven by 93% lower inpatient costs ($297 vs $4215; P = .002), 84% lower outpatient hospital costs ($368 vs $2347; P = .020), and 85% lower other outpatient-related costs ($353 vs $2313; P = .023). Compared with APCDs, FLX was associated with 53% lower total costs ($3973 vs $8436; P = .032) because of lower outpatient costs and lower rates of cellulitis (22.4% vs 44.9% of patients; P = .02).Conclusions
This analysis indicates significant benefits attributable to FLX compared with alternative compression therapies that can help reduce the notable economic burden of phlebolymphedema. 相似文献2.
Javed Butler Mei Yang Massimiliano Alfonzo Manzi Gregory P. Hess Mahesh J. Patel Thomas Rhodes Michael M. Givertz 《Journal of the American College of Cardiology》2019,73(8):935-944
Background
Epidemiology of patients with worsening heart failure and reduced ejection fraction (HFrEF) in the real-world setting is not well described.Objectives
The purpose of this study was to describe incidence, clinical characteristics, treatment, and outcomes of patients with HFrEF who develop worsening heart failure (HF) in the real-world setting.Methods
Data on patients with incident HFrEF from the National Cardiovascular Data Registry PINNACLE were linked to pharmacy, private practitioner, and hospital claims databases. Incidence, clinical characteristics, treatment (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralocorticoid receptor antagonist) and outcomes of patients with worsening HF, defined as ≥90 days of stable HF with subsequent worsening requiring intravenous diuretic agents, were assessed.Results
Of 11,064 HFrEF patients, 1,851 (17%) developed worsening HF on average 1.5 years following initial HF diagnosis. Patients who developed worsening HF were more likely to be African American, be octogenarians, and have higher comorbidity burden (p < 0.001). At the onset of worsening HF, 42.4% of patients were on monotherapy, 43.4% were on dual therapy, and 14.1% were on triple therapy. A total of 48%, 61%, and 98% of patients were on >50% target dose for angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralocorticoid receptor antagonist, respectively. The 2-year mortality rate was 22.5%, and 56% of patients were rehospitalized within 30 days of the worsening HF event.Conclusions
In the real-world setting, 1 in 6 patients with HFrEF develop worsening HF within 18 months of HF diagnosis. These patients have a high risk for 2-year mortality and recurrent HF hospitalizations. The use of standard-of-care therapies both before and after the onset of worsening HF is low. With high unmet medical need, patients with worsening HF require novel treatment strategies as well as greater optimization of existing guideline-directed therapy. 相似文献3.
Arvind Kumar John Z. Deng Vignesh Raman Olugbenga T. Okusanya Ioana Baiu Mark F. Berry Thomas A. D'Amico Chi-Fu Jeffrey Yang 《Seminars in thoracic and cardiovascular surgery》2021,33(2):535-544
- Download : Download high-res image (280KB)
- Download : Download full-size image
4.
Daniel J. Snyder Thomas R. Kroshus Aakash Keswani Evan B. Garden Karl M. Koenig Kevin J. Bozic David S. Jevsevar Jashvant Poeran Calin S. Moucha 《The Journal of arthroplasty》2019,34(4):613-618
Background
Nursing Home Compare (NHC) ratings, created and maintained by Medicare, are used by both hospitals and consumers to aid in the skilled nursing facility (SNF) selection process. To date, no studies have linked NHC ratings to actual episode-based outcomes. The purpose of this study was to evaluate whether NHC ratings are valid predictors of 90-day complications, readmission, and bundle costs for patients discharged to an SNF after primary total joint arthroplasty (TJA).Methods
All SNF-discharged primary TJA cases in 2017 at a multihospital academic health system were queried. Demographic, psychosocial, and clinical variables were manually extracted from the health record. Medicare NHC ratings were then collected for each SNF. For patients in the Medicare bundle, postacute and total bundle cost was extracted from claims.Results
Four hundred eighty-eight patients were discharged to a total of 105 unique SNFs. In multivariate analysis, overall NHC rating was not predictive of 90-day readmission/major complications, >75th percentile postacute cost, or 90-day bundle cost exceeding the target price. SNF health inspection and quality measure ratings were also not predictive of 90-day readmission/major complications or bundle performance. A higher SNF staffing rating was independently associated with a decreased odds for >75th percentile 90-day postacute spend (odds ratio, 0.58; P = .01) and a 90-day bundle cost exceeding the target price (odds ratio = 0.69; P = .02) but was similarly not predictive of 90-day readmission/complications.Conclusion
Results of our study suggest that Medicare's NHC tool is not a useful predictor of 90-day costs, complications, or readmissions for SNFs within our health system. 相似文献5.
6.
Anela Stanic Denis Rybin Francis Cannata Carole Hohl Jennifer Brody Jessie Gaeta 《AIDS care》2021,33(1):1-9
ABSTRACT The lack of stable housing can impair access and continuity of care for patients living with human immunodeficiency virus (HIV). This study investigated the relationship between housing status assessed at multiple time points and several core HIV-related outcomes within the same group of HIV patients experiencing homelessness. Patients with consistently stable housing (CSH) during the year were compared to patients who lacked CSH (non-CSH group). The study outcomes included HIV viral load (VL), CD4 counts, and health care utilization. Multivariable and propensity weighted analyses were used to assess outcomes adjusting for potential group differences. Of 208 patients, 88 (42%) had CSH and 120 (58%) were non-CSH. Patients with CSH had significantly higher proportion of VL suppression and higher mean CD4 counts. The frequency of nurse visits in the CSH group was less than a half of that in the non-CSH group. Patients with CSH were less likely to be admitted to the medical respite facility, and if admitted, their length of stay was about a half of that for the non-CSH group. Our study findings show that patients with CSH had significantly better HIV virologic control and immune status as well as improved health care utilization. 相似文献
7.
8.
ABSTRACTPurpose: To discuss the use of tocilizumab in mild to severe Graves’ ophthalmopathy as corticosteroid-adjunctive therapy. Methods: Retrospective case reports.Results: Three patients with corticosteroid-resistant or advanced diplopia-associated Graves’ ophthalmopathy were subsequently treated with monthly intravenous tocilizumab at a dose of 8 mg/kg. None reported a past or present history of dysthyroidism. The adjunction of interleukin-6-receptor monoclonal antibody treatment was associated with a significant improvement in ocular symptoms, notably diplopia and proptosis, and functional prognosis in all patients, with one relapse approximately two months after the end of the treatment.Conclusion: These clinical reports confirm the relative efficacy and tolerability profile of intravenous tocilizumab in severe or corticosteroid-resistant Graves’ ophthalmopathy. 相似文献
9.
Kristen E. Rhodin Vignesh Raman Oliver K. Jawitz Soraya L. Voigt Norma E. Farrow David H. Harpole Betty C. Tong Thomas A. D’Amico 《The Annals of thoracic surgery》2021,111(2):440-447
- Download : Download high-res image (251KB)
- Download : Download full-size image
10.
Alireza Aminsharifi Lauren E. Howard Christopher L. Amling William J. Aronson Matthew R. Cooperberg Christopher J. Kane Martha K. Terris Thomas J. Polascik Stephen J. Freedland 《Clinical genitourinary cancer》2019,17(1):e140-e149